Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
SmithKline Beecham’s emphasis on prescription to over-the-counter product switches could pay dividends for one of its stable of New York agencies in 1993.
Sources said last week that the big drug and consumer products client is on the verge of tapping Ogilvy & Mather/N.Y. for its Tagamet antiulcer drug.
The client reportedly wants an advertising agency ready and waiting if the Food and Drug Administration gives its approval this year for a consumer version of the best-selling drug, which goes off patent in 1994.
SKB filed an application for an OTC version of Tagamet last December and has been waiting for a thumbs up from the FDA.
While a Tagamet rollout is still a long way off, sources said the product could eventually grow into a $10-15-million plus account.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in